1-(3,4-dimethylphenyl)-2,2-dimethylpropan-1-one | 7397-00-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(3,4-dimethylphenyl)-2,2-dimethylpropan-1-one
• 英文别名: 4-Pivaloyl-o-xylene；1-(3,4-Dimethyl-phenyl)-2,2-dimethyl-propan-1-on；2,2,3',4'-Tetramethylpropiophenone
• CAS: 7397-00-4
• 化学式: C₁₃H₁₈O
• 分子量: 190.285
• InChiKey: DRXPDJIYWNCJPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2914399090

反应信息

• 作为反应物：
  描述：

  1-(3,4-dimethylphenyl)-2,2-dimethylpropan-1-one 在 sodium tetrahydroborate 、 正丁基锂 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 [1-(3,4-Dimethylphenyl)-2,2-dimethylpropyl] 4-methylbenzenesulfonate
  参考文献：
  名称：

  替代效应。22. α-t-丁基苄基甲苯磺酸盐的溶剂分解

  摘要：

  在 80% 的丙酮水溶液 (80A) 和 80% 的乙醇水溶液 (80E) 中测定了甲苯磺酸 α-叔丁基苄基酯的溶剂分解速率，以获得一系列扩展的取代基。根据 Yukawa-Tsuno LArSR 关系，取代基效应可以线性相关，80A 中的 ρ 值分别为 -5.542 和 1.093，80E 中的 ρ 值分别为 -5.650 和 1.106。大的负 ρ 和升高的 r 值表明 kc 机制在没有亲核溶剂辅助和甲基参与的情况下在这种溶剂分解中起作用。从取代基效应的比较来看，在 α-甲基苄基氯的溶剂分解中观察到的 1.15 的升高 r 值可归因于二级苄基系统增强的共振需求特征，而不是由 SN1-SN2 引起的非线性引起的相关伪影机械变化。

  DOI：

  10.1246/bcsj.63.856
• 作为产物：
  描述：

  4-溴-1,2-二甲苯 、 三甲基乙酰氯 在 magnesium 作用下， 生成 1-(3,4-dimethylphenyl)-2,2-dimethylpropan-1-one
  参考文献：
  名称：

  替代效应。22. α-t-丁基苄基甲苯磺酸盐的溶剂分解

  摘要：

  在 80% 的丙酮水溶液 (80A) 和 80% 的乙醇水溶液 (80E) 中测定了甲苯磺酸 α-叔丁基苄基酯的溶剂分解速率，以获得一系列扩展的取代基。根据 Yukawa-Tsuno LArSR 关系，取代基效应可以线性相关，80A 中的 ρ 值分别为 -5.542 和 1.093，80E 中的 ρ 值分别为 -5.650 和 1.106。大的负 ρ 和升高的 r 值表明 kc 机制在没有亲核溶剂辅助和甲基参与的情况下在这种溶剂分解中起作用。从取代基效应的比较来看，在 α-甲基苄基氯的溶剂分解中观察到的 1.15 的升高 r 值可归因于二级苄基系统增强的共振需求特征，而不是由 SN1-SN2 引起的非线性引起的相关伪影机械变化。

  DOI：

  10.1246/bcsj.63.856

文献信息

• Palladium-Catalyzed Intermolecular Directed C−H Amidation of Aromatic Ketones
  作者：Bin Xiao、Tian-Jun Gong、Jun Xu、Zhao-Jing Liu、Lei Liu

  DOI：10.1021/ja108450m

  日期：2011.2.9

  Pd-catalyzed directed ortho C-H amidation of aromatic ketones with both sulfonamides and amides has been accomplished. The use of an electron-deficient Pd complex, Pd(OTf)(2), is crucial for the success of this transformation. Some key intermediates of the reaction, that is, the cyclopalladation complexes of ketones, have been characterized by X-ray crystallography. Experimental analysis of these palladacycles

  已经完成了 Pd 催化的芳香酮与磺酰胺和酰胺的定向邻位 CH 酰胺化。使用缺电子的 Pd 复合物 Pd(OTf)(2) 对这种转变的成功至关重要。该反应的一些关键中间体，即酮的环钯化配合物，已通过 X 射线晶体学表征。这些钯环的实验分析以及 N-甲基磺酰胺的实验结果表明，新反应似乎没有通过氮烯中间体进行。新开发的反应可用于合成有用的有机中间体，例如 2- 和 3- 烷基吲哚和 2- 氨基苯基酮。
• Alkanoyl isoindolinylmethyl alkylphenones
  申请人：Sandoz, Inc.

  公开号：US04000307A1

  公开（公告）日：1976-12-28

  Alkanoyl isoindolinylmethyl alkylphenones of the formula, ##STR1## e.g. 4'-(5-pivaloyl-2-isoindolinylmethyl)-pivalophenone, are prepared by reacting a 3',4'-bis(bromomethyl)alkylphenone with a 4'-(aminomethyl)alkylphenone-(2,2-dimethyl-1,3-propanediyl)cyclic ketal and hydrolyzing the ketal formed, and are useful as hypolipidemic agents.

  式子为##STR1##的酰基异吲哚甲基烷基苯酮，例如4'-(5-异戊酰基-2-异吲哚甲基)-异戊酮，通过将3',4'-双(溴甲基)烷基苯酮与4'-(氨甲基)烷基苯酮-(2,2-二甲基-1,3-丙二醇)环缩酮反应，并水解所形成的环缩酮制备而成，可用作降血脂药物。
• MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：MUTO Susumu

  公开号：US20080234233A1

  公开（公告）日：2008-09-25

  A medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease or the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is circle around (1)} a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, circle around (2)} unsubstituted thiazol-2-yl group, or circle around (3)} unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above.

  这是一种用于预防和/或治疗神经退行性疾病，如阿尔茨海默病等的药物，其包括以下通式（I）所表示的化合物中所选的一种作为活性成分，以及其药学上可接受的盐、水合物和溶剂化合物：其中，A代表氢原子或乙酰基，E代表2,5-二取代或3,5-二取代苯基，或单环或融合的多环杂环芳基，可以取代，但是当所述杂环芳基为圆圈1}在公式（I）中直接结合—CONH—基团的环为苯环，圆圈2}未取代的噻唑-2-基团，或圆圈3}未取代的苯并噻唑-2-基团时，排除在外，环Z代表一个芳烃，除了由公式—O-A所表示的基团和由公式—CONH-E所表示的基团外，还可以有一个或多个取代基，其中A具有上述定义的相同含义，E具有上述定义的相同含义，或者代表一个杂芳烃，除了由公式—O-A所表示的基团和由公式—CONH-E所表示的基团外，还可以有一个或多个取代基。
• ANTIALLERGIC AGENTS
  申请人：Muto Susumu

  公开号：US20080090779A1

  公开（公告）日：2008-04-17

  A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物，其包括以下通式（I）所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分，其中X表示连接基，其主链中原子数为2至5（该连接基可以被取代），A表示氢原子或乙酰基，E表示芳基或取代的杂芳基，环Z表示苯环，除了由公式-O-A表示的基团，该苯环还可以具有一个或多个取代基团，其中A的含义与上述定义相同，而由公式-X-E表示的基团中，每个X和E的含义也与上述定义相同，或者是一个杂环，除了由公式-O-A表示的基团，该杂环还可以具有一个或多个取代基团，其中A的含义与上述定义相同，而由公式-X-E表示的基团中，每个X和E的含义也与上述定义相同。
• Antiallergic agents
  申请人：Muto Susumu

  公开号：US20070185059A1

  公开（公告）日：2007-08-09

  A medicament for the preventive and/or therapeutic treatment of allergic diseases and/or endometriosis and/or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种用于预防和/或治疗过敏性疾病和/或子宫内膜异位症和/或子宫肌瘤的药物，其活性成分包括以下通式（I）表示的化合物或其药学上可接受的盐、水合物和溶剂化物中的一种，其中X代表连接基，其主链中的原子数为2到（该连接基可以被取代），A代表氢原子或乙酰基，E代表芳基或取代的杂环芳基，环Z代表芳烃，除了由公式-O-A表示的基团外，还可以有一个或多个取代基，其中A具有上述定义的相同含义，并且由公式-X-E表示的基团，其中X和E的每个都具有上述定义的相同含义，或者可以有一个或多个取代基的杂芳烃，其中A具有上述定义的相同含义，并且由公式-X-E表示的基团，其中X和E的每个都具有上述定义的相同含义。